• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Interactions of the public and private sectors in drug development: boundaries to protect scientific values while preserving innovation.

作者信息

Cassell Gail H

机构信息

Eli Lilly and Company, Indianapolis, IN 46285, USA.

出版信息

Cleve Clin J Med. 2007 Mar;74 Suppl 2:S45-8; discussion S51-9. doi: 10.3949/ccjm.74.suppl_2.s45.

DOI:10.3949/ccjm.74.suppl_2.s45
PMID:17469473
Abstract

Industry, academia, and government have developed highly interwoven relationships in the pursuit of biomedical research. Establishing and maintaining boundaries among the public and private sectors at both the institutional level and the individual level is critical to protect core scientific values, preserve innovation, and allow product development to thrive. This article reviews principles that guide the interactions of these Biomdifferent sectors, sharing principles in place at Eli Lilly and Company as an example.

摘要

相似文献

1
Interactions of the public and private sectors in drug development: boundaries to protect scientific values while preserving innovation.
Cleve Clin J Med. 2007 Mar;74 Suppl 2:S45-8; discussion S51-9. doi: 10.3949/ccjm.74.suppl_2.s45.
2
Innovation and industry-academia interactions: where conflicts arise and measures to avoid them.
Cleve Clin J Med. 2007 Mar;74 Suppl 2:S12-3; discussion 16-22. doi: 10.3949/ccjm.74.suppl_2.s12.
3
Ethics. Private money, public disclosure.伦理。私人资金,公开披露。
Science. 2009 Jul 3;325(5936):28-30. doi: 10.1126/science.325_28.
4
Fostering innovation without compromising integrity.在不损害诚信的前提下促进创新。
Cleve Clin J Med. 2007 Mar;74 Suppl 2:S10-1; discussion 16-22. doi: 10.3949/ccjm.74.suppl_2.s10.
5
Beyond disclosure: the necessity of trust in biomedical research.超越披露:生物医学研究中信任的必要性。
Cleve Clin J Med. 2007 Mar;74 Suppl 2:S49-50; discussion S51-9. doi: 10.3949/ccjm.74.suppl_2.s49.
6
Relationships Between Academic Medicine Leaders and Industry-Time for Another Look?学术医学领袖与行业之间的关系——是否需要重新审视?
JAMA. 2020 Nov 10;324(18):1833-1834. doi: 10.1001/jama.2020.21021.
7
Is industry money the root of all conflicts of interest in biomedical research?行业资金是生物医学研究中所有利益冲突的根源吗?
Ann Emerg Med. 2012 Feb;59(2):87-8. doi: 10.1016/j.annemergmed.2011.03.001. Epub 2011 Apr 2.
8
Overregulation of conflicts hinders medical progress.对冲突的过度管控阻碍医学进步。
Cleve Clin J Med. 2007 Mar;74 Suppl 2:S14-5; discussion S16-22. doi: 10.3949/ccjm.74.suppl_2.s14.
9
The challenge for NIH ethics policies: preserving public trust and biomedical progress.美国国立卫生研究院伦理政策面临的挑战:维护公众信任与生物医学进步。
Cleve Clin J Med. 2007 Mar;74 Suppl 2:S29-31; discussion S32-7. doi: 10.3949/ccjm.74.suppl_2.s29.
10
NerveCenter: Office of Inspector General warns NIH on lax COI oversight as many academic medical centers look inward.神经中枢:随着许多学术医疗中心进行自查,美国监察长办公室就国立卫生研究院对利益冲突监督不力发出警告。
Ann Neurol. 2010 Mar;67(3):A7-A10. doi: 10.1002/ana.22026.